KR102405462B1 - Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논 - Google Patents

Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논 Download PDF

Info

Publication number
KR102405462B1
KR102405462B1 KR1020167019551A KR20167019551A KR102405462B1 KR 102405462 B1 KR102405462 B1 KR 102405462B1 KR 1020167019551 A KR1020167019551 A KR 1020167019551A KR 20167019551 A KR20167019551 A KR 20167019551A KR 102405462 B1 KR102405462 B1 KR 102405462B1
Authority
KR
South Korea
Prior art keywords
methyl
amino
pyrimidin
phenyl
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167019551A
Other languages
English (en)
Korean (ko)
Other versions
KR20160098499A (ko
Inventor
티모시 해리슨
그라함 트레빗
피터 로빈 휴윗
콜린 로데릭 오다우드
프랭크 벌캠프
앤드류 존 윌킨슨
스티븐 디 쉐퍼드
위그 미엘
Original Assignee
알막 디스커버리 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알막 디스커버리 리미티드 filed Critical 알막 디스커버리 리미티드
Publication of KR20160098499A publication Critical patent/KR20160098499A/ko
Application granted granted Critical
Publication of KR102405462B1 publication Critical patent/KR102405462B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167019551A 2013-12-19 2014-12-19 Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논 Active KR102405462B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322602.2 2013-12-19
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20160098499A KR20160098499A (ko) 2016-08-18
KR102405462B1 true KR102405462B1 (ko) 2022-06-03

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167019551A Active KR102405462B1 (ko) 2013-12-19 2014-12-19 Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논

Country Status (28)

Country Link
US (1) US9850247B2 (enExample)
EP (1) EP3083625B1 (enExample)
JP (1) JP6437559B2 (enExample)
KR (1) KR102405462B1 (enExample)
CN (1) CN105829315B (enExample)
AU (1) AU2014369457B2 (enExample)
BR (1) BR112016014151B1 (enExample)
CA (1) CA2933755C (enExample)
CY (1) CY1120035T1 (enExample)
DK (1) DK3083625T3 (enExample)
ES (1) ES2650013T3 (enExample)
GB (1) GB201322602D0 (enExample)
HR (1) HRP20180080T1 (enExample)
HU (1) HUE037908T2 (enExample)
IL (1) IL245672B (enExample)
LT (1) LT3083625T (enExample)
MX (1) MX371108B (enExample)
NO (1) NO3083625T3 (enExample)
NZ (1) NZ720178A (enExample)
PL (1) PL3083625T3 (enExample)
PT (1) PT3083625T (enExample)
RS (1) RS56731B1 (enExample)
RU (1) RU2691105C1 (enExample)
SG (1) SG11201603814TA (enExample)
SI (1) SI3083625T1 (enExample)
SM (1) SMT201800020T1 (enExample)
WO (1) WO2015092431A1 (enExample)
ZA (1) ZA201603337B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137593B (zh) * 2015-04-21 2021-01-05 上海交通大学医学院附属瑞金医院 蛋白激酶抑制剂的制备和用途
CA3003737C (en) 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
JP7240784B2 (ja) * 2016-11-16 2023-03-16 上海瑛派▲薬▼▲業▼有限公司 ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
ES2902050T3 (es) 2017-01-23 2022-03-24 Shijiazhuang Sagacity New Drug Dev Co Ltd Derivado 1,2-dihidro-3H-pirazolo[3,4-D]pirimidin-3-ona como inhibidor de Wee1
GB201703881D0 (en) 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
WO2019011228A1 (zh) * 2017-07-10 2019-01-17 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074981A1 (en) 2017-10-09 2019-04-18 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
PT3712150T (pt) 2017-11-01 2024-08-22 Wuxi Biocity Biopharmaceutics Co Ltd Composto macrocíclico que serve como inibidor wee1 e aplicações do mesmo
CA3088997A1 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
US20230065740A1 (en) 2018-12-28 2023-03-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
JP2022528047A (ja) 2019-03-22 2022-06-08 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド Ｗｅｅ１阻害剤、その製造および用途
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210375A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US12291536B2 (en) 2019-04-30 2025-05-06 Wuxi Biocity Biopharmaceutics Co., Ltd. Crystal form of Wee1 inhibitor compound and use thereof
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
US12522607B2 (en) 2020-06-17 2026-01-13 Wigen Biomedicine Technology (shanghai) Co., Ltd. Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors
US20230416247A1 (en) * 2020-10-01 2023-12-28 University Of Washington Drug-like molecules and methods for the therapeutic targeting of microrna-21
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
CA3202328A1 (en) * 2020-12-18 2022-06-23 Jie GUANG Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases
TW202239409A (zh) * 2020-12-18 2022-10-16 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
EP4332104A4 (en) 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
WO2022270994A1 (ko) 2021-06-25 2022-12-29 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
WO2025101691A1 (en) 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012161812A1 (en) 2011-02-28 2012-11-29 Abbott Laboratories Tricyclic inhibitors of kinases
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
WO2005090344A1 (en) 2004-03-15 2005-09-29 F. Hoffmann-La Roche Ag Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
CA2689429C (en) 2007-06-15 2012-08-21 Banyu Pharmaceutical Co., Ltd. Bicycloaniline derivatives
US8329711B2 (en) 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
US8575179B2 (en) * 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
AR084515A1 (es) * 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
US8716297B2 (en) 2011-07-15 2014-05-06 Abbvie Inc. Chemical entities to be used for Wee1 inhibition for the treatment of cancer
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012161812A1 (en) 2011-02-28 2012-11-29 Abbott Laboratories Tricyclic inhibitors of kinases
WO2013013031A1 (en) 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
WO2013059485A1 (en) 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases

Also Published As

Publication number Publication date
CY1120035T1 (el) 2018-12-12
GB201322602D0 (en) 2014-02-05
PL3083625T3 (pl) 2018-03-30
SMT201800020T1 (it) 2018-05-02
BR112016014151A2 (enExample) 2017-08-08
US9850247B2 (en) 2017-12-26
HUE037908T2 (hu) 2018-09-28
CA2933755A1 (en) 2015-06-25
IL245672A0 (en) 2016-06-30
MX371108B (es) 2020-01-17
CN105829315A (zh) 2016-08-03
LT3083625T (lt) 2017-12-27
ZA201603337B (en) 2018-07-25
KR20160098499A (ko) 2016-08-18
EP3083625B1 (en) 2017-11-01
AU2014369457B2 (en) 2018-08-09
RU2691105C1 (ru) 2019-06-11
NZ720178A (en) 2022-05-27
JP2017500335A (ja) 2017-01-05
NO3083625T3 (enExample) 2018-03-31
HRP20180080T1 (hr) 2018-03-09
CN105829315B (zh) 2019-03-08
BR112016014151B1 (pt) 2023-01-17
RU2016123363A (ru) 2018-01-25
EP3083625A1 (en) 2016-10-26
IL245672B (en) 2021-10-31
PT3083625T (pt) 2018-02-06
SG11201603814TA (en) 2016-07-28
DK3083625T3 (en) 2017-12-18
AU2014369457A1 (en) 2016-06-09
US20160318936A1 (en) 2016-11-03
CA2933755C (en) 2023-01-31
JP6437559B2 (ja) 2018-12-12
WO2015092431A1 (en) 2015-06-25
MX2016007801A (es) 2016-09-07
SI3083625T1 (en) 2018-03-30
RS56731B1 (sr) 2018-03-30
ES2650013T3 (es) 2018-01-16

Similar Documents

Publication Publication Date Title
AU2014369457B2 (en) Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors
JP7073359B2 (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
US10766902B2 (en) Wee-1 inhibiting pyrazolopyrimidinone compounds
JP6412920B2 (ja) ２−アミノピリド［４，３−Ｄ］ピリミジン−５−オン誘導体及びＷｅｅ−１阻害薬としてのそれらの使用
WO2018011570A1 (en) Wee-1 inhibiting pyridopyrimidinone compounds
WO2015019037A1 (en) Pharmaceutical compounds
HK1227877B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1227877A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
CN115843296B (zh) Cdk9抑制剂及其用途
HK1219474B (en) 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4